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3,5,3′-triiodo-L-thyronine (T3) and 3,5-diiodo-L-thyronine (T2), when administered
to a model of familial hypercholesterolemia, i.e., low density lipoprotein receptor
(LDLr)-knockout (Ldlr−/−) mice fed with a Western type diet (WTD), dramatically reduce
circulating total and very low-density lipoprotein/LDL cholesterol with decreased liver
apolipoprotein B (ApoB) production. The aim of the study was to highlight putative
molecular mechanisms to manage cholesterol levels in the absence of LDLr. A
comprehensive comparative profiling of changes in expression of soluble proteins in
livers from Ldlr−/− mice treated with either T3 or T2 was performed. From a total
proteome of 450 liver proteins, 25 identified proteins were affected by both T2 and T3,
18 only by T3 and 9 only by T2. Using in silico analyses, an overlap was observed with
11/14 pathways common to both iodothyronines, with T2 and T3 preferentially altering
sub-networks centered around hepatocyte nuclear factor 4 α (HNF4α) and peroxisome
proliferator-activated receptor α (PPARα), respectively. Both T2 and T3 administration
significantly reduced nuclear HNF4α protein content, while T2, but not T3, decreased the
expression levels of the HNFα transcriptional coactivator PGC-1α. Lower PPARα levels
were found only following T3 treatment while both T3 and T2 lowered liver X receptor
α (LXRα) nuclear content. Overall, this study, although it was not meant to investigate
the use of T2 and T3 as a therapeutic agent, provides novel insights into the regulation
of hepatic metabolic pathways involved in T3- and T2-driven cholesterol reduction in
Ldlr−/− mice.
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INTRODUCTION
Familial hypercholesterolemia (FH) is a common inherited disorder resulting from mutations
in the low-density lipoprotein receptor (LDLr) gene leading to defects in LDL cholesterol
(LDL-C) clearance. Despite the use of currently available cholesterol-lowering treatments,
a high proportion of FH patients do not reach treatment goals and remain at risk of
atherosclerotic cardiovascular diseases (Naoumova et al., 2004). More intensive and alternative
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treatments are often needed for these patients as well as other
hypercholesterolemic patients who do not meet treatment goals
or who have difficulty with statin therapy. One possible approach
to cholesterol reduction is via activation of hepatic thyroid
receptors (TRs).
Both 3,5,3′,5′-tetraiodo-L-thyronine (T4), and 3,5,3′-triiodo-
L-thyronine (T3) (THs) reduce circulating cholesterol in animals
and humans (Klein and Danzi, 2008; Angelin and Rudling,
2010). However, their therapeutic use for the treatment of
hyperlipidemia is limited due to deleterious side effects from TR
activation in extrahepatic tissues leading to altered cardiovascular
function, muscle wasting, and bone loss (Scheiffele and Schultze,
1972). In recent years, several thyromimetics (i.e., GC1 and
KB2115) have been developed that selectively activate TRβ, the
predominant TR isoform in the liver that is primarily responsible
for the effects on cholesterol and lipoprotein metabolism exerted
by T3 (Johansson et al., 2005; Erion et al., 2007; Tancevski
et al., 2010; Pramfalk et al., 2011). These compounds retard
atherosclerosis progression in animals and exert favorable
lipid-modulating effects in humans, while lacking THs-related
thyrotoxic side-effects (Bakker et al., 1998; Erion et al., 2007;
Baxter and Webb, 2009; Pedrelli et al., 2010). However, side
effects may limit its clinical use since the cholesterol-reducing
thyrometic eprotirome (Ladenson et al., 2010) was recently
shown to elevate circulating liver enzymes (Sjouke et al., 2014), a
sign of liver damage and, indeed, development of eprotirome was
terminated after cartilage damage was observed in a toxicological
study in dogs.
Hepatic TR activation might lower cholesterol levels via
multiple mechanisms. Although the primary hepatic effects on
cholesterol metabolism of THs was thought to be via LDL
clearance through increased expression of LDLr (Ness and Lopez,
1995), we and others have reported that iodothyronines [T3 and
3,5-diiodo-L-thyronine (T2)] as well as GC1 markedly reduce
circulating LDL-C in LDLr knockout (Ldlr−/−) mice (Goldberg
et al., 2012; Lin et al., 2012). These studies and those of others
(Davidson et al., 1988, 1990) show that both iodothyronines
lead to a reduction in hepatic secretion of apolipoprotein B
(ApoB)-containing lipoproteins [very low density lipoproteins
(VLDL) and LDL] while high density lipoprotein (HDL) levels
are reduced only by T3 (Goldberg et al., 2012).
This reduction is not associated with increased hepatic
protein or mRNA levels of LDL receptor related protein
(LRP) 1 or the scavenger receptor-B1 (SR-B1) (Goldberg
et al., 2012). Cholesterol reduction was also reported to
be associated with increased expression of cholesterol-7
α-hydroxylase (Cyp7a1) (Lin et al., 2012), which converts
cholesterol into bile acids. These studies (Goldberg et al.,
2012; Lin et al., 2012) dispelled the conventional view that
thyroid-mediated reduction of cholesterol requires LDLr
and indicated that the thyroid hormone responsive element
(TRE) in the LDL receptor is not required in vivo for
thyroid-induced LDL reduction. Although our previous
study (Goldberg et al., 2012) with high doses of T3 and T2 was
not meant to investigate their use as therapeutic agents, the
elicited dramatic reduction in circulating cholesterol levels in
hypercholesterolemic Ldlr−/− mice opened new perspectives
in defining non-LDLr pathways that may have potential for the
treatment of hypercholesterolemia.
The goal of the following study was to gain additional insights
into the molecular factors and pathways that contribute to the
above hypocholesterolemic actions of T2 and T3. To uncover the
pathways and networks altered by these two iodothyronines, we
performed a comprehensive comparative profiling of changes in
expression of soluble proteins in livers from Ldlr−/− mice treated
with either T3 or T2.
MATERIALS AND METHODS
Animals and Experimental Protocol
All studies were approved by the Columbia University
Institutional Animal Care and Use Committee (IACUC).
Male wild-type (WT) C57BL/6 and Ldlr−/− mice of 3–4
months of age, purchased from the Jackson Laboratory, were
used. WT C57BL/6 and Ldlr−/− mice (n = 5–6/group) were
fed a Western-type diet (WTD) containing: 42% fat, 42.7%
carbohydrate, 15.2% protein, 0.15% cholesterol; total 4.5 Kcal/g
(Harlan Teklad) for 1 week. After 1 week, C57BL/6 and
Ldlr−/− mice were continued on the WTD and were divided
into groups receiving vehicle (58.5% saline + 40% DMSO +
1.5% 1M NaOH) or iodothyronines—T3 (0.75mg/kg) (EMD
Chemicals/Calbiochem) or T2 (12.5 mg/kg) (Santa Cruz)—via
daily gavage for another week and then sacrificed. The doses of
T3 and T2 were chosen to obtain the same cholesterol reducing
effect (Goldberg et al., 2012). Mass spectrometry and NMR
profiles showed no T3 or T4 contamination in the T2. All blood
samples obtained during the non-terminal portion of the study
were taken after a 4-h fast.
Protein Extraction and Sample Preparation
for Two-Dimensional Gel Electrophoresis
(2D-E)
Protein extraction and sample preparation for 2D-E were
performed as reported in Silvestri et al. (2006). Liver tissue was
suspended in sample buffer [20 mMTris, 7 M urea, 2 M thiourea,
4% CHAPS, 10 mM 1,4-dithioerythritol (DTE), 1 mM EDTA,
and a mixture of protease and phosphatase inhibitors]. The
suspensions were homogenized using a Polytron homogenizer,
sonicated for 30 s, and centrifuged at 150,000 g for 45 min.
The obtained supernatants contained the total liver proteins
solubilized in the isoelectrofocusing (IEF)-compatible agents.
The protein content of each sample was determined by Bio-Rad’s
DC method (Bio-Rad Laboratories, Hercules, CA). Total protein
extracts were prepared for each animal, and each individual was
assessed separately.
2D-E
Samples of 650µg of protein were applied to immobilized pH
gradient (IPG) strips (pH 4–7, 17 cm) (Bio-Rad). Samples of
1mg of protein were utilized for preparative gels (IPG strips, pH
4–7, 17 cm). Focusing started at 200 V, with the voltage being
gradually increased to 3500 V and kept constant for a further
66,500 V/h (PROTEAN IEF System, Bio-Rad). Prior to SDS-
PAGE, the IPG strips were incubated for 15 min with a solution
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of Tris-HCl buffer (pH 8.8), urea (6 M), glycerol (30%, v/v), SDS
(2%, w/v), and DTT (2%, w/v). Strips were then equilibrated
for another 15 min in the same buffer containing iodoacetamide
(2.5%, w/v) instead of DTT. The second-dimensional separation
was performed in 12% SDS-polyacrylamide gels. After protein
fixation, the gels were stained with colloidal Coomassie Blue,
according to the manufacturer’s instructions. Molecular masses
were determined by running standard protein markers, covering
the range 10–200 kDa. The pI values used were those given by the
supplier of the IPG strips.
Protein Visualization and Image Analysis
Digital images of the gels were recorded using a calibrated
densitometer (GS-800, Bio-Rad) and analyzed using PDQuest
software (Bio-Rad) (Silvestri et al., 2006). For each matchset
analysis, maps corresponding to protein extracts from animals
of the same experimental group were organized into “Replicate
Groups” (each containing 4maps), named Ldlr−/−, Ldlr−/−+T2,
and Ldlr−/−+T3. Statistical analysis was performed using a
Student’s t-test. Spots for which the p-value was <0.05 were
considered to display significant changes.
Protein Digestion and Mass Spectrometry
Analysis
Spots from 2D-E were manually excised from gels, triturated, and
washed with water. Proteins were in-gel reduced, S-alkylated, and
digested with trypsin, as previously reported (D’Ambrosio et al.,
2008). Protein digests were subjected to a desalting/concentration
step on µZipTipC18 pipette tips (Millipore Corp., Bedford, MA,
USA) and then analyzed by nano-liquid chromatography (nLC)-
electrospray ionization (ESI)-linear ion trap (LIT)-tandem
(MS/MS) mass spectrometry, using a LTQ XL mass spectrometer
(Thermo Fischer Scientific, USA) equipped with a Proxeon
nanospray source connected to an Easy-nanoLC (Proxeon,
Odense, Denmark). Peptide mixtures were separated on an Easy
C18 column (100 × 0.075 mm, 3 µm) (Thermo, USA) using a
gradient of acetonitrile containing 0.1% formic acid in aqueous
0.1% formic acid; acetonitrile was ramped from 5 to 35% over 10
min, from 35 to 95% over 2 min, and remained at 95% for 12min,
at a flow rate of 300 nL/min. Spectra were acquired in the range
m/z 400–2000. Acquisition was controlled by a data-dependent
product ion-scanning procedure over the 3 most abundant ions,
enabling dynamic exclusion (repeat count 2; exclusion duration
1 min). The mass isolation window and collision energy were set
to m/z 3 and 35%, respectively.
Protein Identification
MASCOT software package version 2.2.06 (Matrix Science, UK)
(Cottrell, 2011) was used to identify spots unambiguously from a
MusMusculus protein sequence database retrieved from UniProt
repository (76,058 sequences, 10/2011). Raw data from nanoLC-
ESI-LIT-MS/MS were searched using a mass tolerance value
of 2 Da for precursor ion and 0.8 Da for MS/MS fragments,
trypsin as proteolytic enzyme, a missed-cleavages maximum
value of 2, and Cys carbamidomethylation and Met oxidation as
fixed and variable modifications, respectively. Protein candidates
with more than 2 assigned peptide sequences, with MS/MS ion
score >30 and a peptide expectation value <0.05, were further
evaluated by comparisonwith their calculatedmass and pI values,
using the experimental values obtained from 2D-E.
In silico Biological Analysis
The lists of differentially expressed proteins were input into the
IPA platform (Ingenuity Systems, http://www.ingenuity.com) for
the identification of canonical pathways and functions differing
between the treatments. The cutoff used was 1.5 for the fold
change and 0.05 for the p-value. Fisher’s exact test was used to
calculate a p-value indicating the probability that each biological
function and/or disease assigned to that dataset might be so
assigned due to chance alone. The results of Fisher’s exact test
were corrected for multiple testing using the false discovery rate
(FDR). Comparison analysis was also performed to compare
the roles of the proteins among the generated lists. In order to
generate the reported networks, a list of differentially expressed
proteins in the experimental conditions was overlaid onto a
global molecular network developed from information contained
in the Ingenuity Pathways Knowledge Base (IPKB). Networks of
these focus-gene products were then algorithmically generated
on the basis of their connectivity. The IPA platform uses a
curated database to construct functional regulatory networks
from a list of individual proteins. To build networks, the program
utilizes the IPKB containing large numbers of individually
modeled relationships between proteins (obtained from the
upgraded literature contained in IPA platform). The algorithm
then determines a statistical score for each network. This is done
by comparing the number of focus proteins that contribute to a
given network relative to the total number of occurrences of those
proteins in all networks or pathways stored in the IPKB. Then
a score is assigned to each network. The score is the negative
log of P, and it denotes the likelihood that the focus proteins
in the network might be found together by chance. Therefore,
scores of 2 have at least 99% confidence of not being generated
by chance alone. In addition, the biological functions assigned
to each network are ranked according to the significance of that
biological function to the network.
Nuclei Preparation and Western
Immunoblot Analysis
As already described in Cioffi et al. (2010), livers were dissected
and minced in ice-cold isolation buffer (consisting of 220 mM
mannitol, 70 mM sucrose, 20 mM Tris-HCl, 1 mM EDTA, and
5 mM EGTA, pH 7.4) and then were homogenized in a Potter-
Elvehjem homogenizer. To isolate nuclei, the liver homogenate
was centrifuged at 500 g for 10 min at 4◦C. The obtained
pellet was subsequently resuspended and spun through a sucrose
cushion (30% sucrose, 10 mM Tris-HCl, pH 7.5, 10 mM NaCl,
and 3 mMMgCl2) at 1300 g for 10 min at 4◦C. The nuclear pellet
was washed with cold 10mMTris-HCl, pH 7.5, and 10mMNaCl.
For Western immunoblotting analysis, the nuclear pellets
were homogenized in lysis buffer containing 20mM Tris-
HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA,
2.5mM Na2H2P2O7, 1mM b-CH3H7O6PNa2, 1mM Na3VO4,
1mM PMSF, 1mg/ml leupeptin, and 1% (w/v) Triton X-100
by using an Optima TLX Ultraturrax (Beckman Coulter,
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Milan, Italy), then centrifuged at 13,400 g for 10 min at
4◦C. Protein concentration was determined by using the Bio
Rad’s DC method (Bio-Rad Laboratories, Hercules, CA). The
following primary antibodies were used: anti-HNF4α (ab41,898,
Abcam,mousemonoclonal); anti-PPARα (ab8934, Abcam, rabbit
polyclonal); anti-LXRα (ab41,902, Abcam, mouse monoclonal);
anti-TRβ (GTX113278, GeneTex, rabbit polyclonal); anti-PGC-
1α (AB3242, Merck Millipore, rabbit polyclonal); anti-α tubulin
(ab4074, Abcam, rabbit polyclonal). Proteins were detected by
a chemiluminescence protein-detection method based on the
protocol supplied with a commercially available kit (Millipore)
and by using the appropriate secondary antibodies. Signals were
quantified by means of a Bio-Rad ChemiDocTM XRS, using
dedicated software (QuantityOne, Bio-Rad Laboratories).
Serum Levels of Free T3 (FT3) and Free T4
(FT4)
The serum levels of FT3 and FT4 weremeasured by commercially
available kits by means of immunoassay [materials and protocols
supplied by Byk-Sangtec Diagnostica (Dietzenbach, Germany)].
Statistical Analysis
Data are expressed as the mean ± SD as indicated in the
figures. Comparisons between two groups were performed
using student’s t-test. Comparisons amongst three groups
were performed using one-way ANOVA and followed by the
Newman-Keuls test. For all analyses, p < 0.05 was considered
statistically significant.
RESULTS
Altered Liver Protein Expression Profile
Induced by T2 and T3
Through a 2D-E-based proteomic approach, the hepatic
pathways and the molecular mediators involved in the T2-
and T3- induced reductions in circulating cholesterol levels
in Ldlr−/− mice were investigated. At the detection-limits set,
the image software counted 450 matched proteins among the
various maps in the liver (Figure 1A). Pair-wise comparisons
were performed to analyze the differential expression pattern
associated with the T2 and T3 treatment (Ldlr−/−+T2 and
Ldlr−/−+T3 vs. Ldlr−/−). When the interest was limited to
a differential expression of at least 2-fold and a statistical
significance of at least 95% (p < 0.05), 57 (about 12.4% of
total entries), and 59 spots (about 12.8% of total entries)
showed significant quantitative changes in liver following T2-
and T3-treatment, respectively. Importantly, the differential
expression produced by T2 and T3 overlapped on 33 protein
products (Figure 1B) corresponding to 40% of the total
amount of differentially expressed proteins (Figure 1E). The
remaining, specifically affected either by T2 (Figure 1C) or
by T3 (Figure 1D), represented 29 and 31% of the total
amount of differentially expressed proteins (Figures 1F,G,
respectively).
Considering that in a previous study (Goldberg et al., 2012) we
demonstrated amodulation exerted by T3 and T2 on intrahepatic
content of apolipoproteins and that ApoE and ApoA1 are well
resolved on a standard 2D map of total soluble liver proteome,
ApoE and ApoA1 were localized by means of map comparison
(Fountoulakis et al., 2001) and subjected to quantitative analysis.
ApoE, corresponding to spot 43 (Figure 1C), was significantly
affected only by T2 with a differential expression of −40%
vs. Ldlr−/− control levels (p < 0.1) (Figure 2). ApoA1,
corresponding to spot 69 (Figure 1D), tended to be reduced in
Ldlr−/−+T3 mice by −40% vs. Ldlr−/− control levels, although
without statistical significance (Figure 2). These two proteins
together with other 67 spots among those automatically detected
by the matching software, were manually excised, trypsinyzed,
and subjected to nanoLC-ESI-LIT-MS/MS analysis. Fifty-two
protein spots were unambiguously identified (Supplementary
Material 1). Among these, 25 protein products were affected by
both T2 and T3, 9 only by T2, 18 only by T3.
Proteins detected as a mixture of components were excluded
from further analyses and thus were not discussed further in
this report. When proteins were identified as multiple spots
on the same map, putatively reflecting the occurrence of post-
translational modifications, the pattern of changes was fairly
similar among the various species.
Analysis of Potential Target Proteins of T2
and T3
Both T2 and T3 reduced expression of a number of hepatic
proteins compared to the expression levels obtained for
Ldlr−/− control mice (91 and 79% of differentially expressed
proteins, respectively). A significant increase produced by both
iodothyronines was observed for cellular retinol-binding protein
1 also named CRBP1 (spot 1) and major urinary protein 1
(MUP1) (spot 2), with the effect of T3 being more pronounced
than that of T2 (Figure 3). Key metabolic enzymes were
among the proteins decreased by both iodothyronines
(Figure 4). Importantly, these enzymes are involved in major
hepatic processes such as amino acid metabolism [catechol
O-methyltransferase (spot 4), ornithine aminotransferase,
mitochondrial (spot 21) and histidine ammonia-lyase (spot 29)]
(Figure 4A), substrate metabolism [aldose 1-epimerase (spot 15),
malate dehydrogenase (spot 17), and fructose-1,6-bisphosphatase
1 (spot 19)] (Figure 4B), and cellular stress [lactoylglutathione
lyase (spot 3), regucalcin (spot 13), mitochondrial aldehyde
dehydrogenase (spot 25)] (Figure 4C). Of note, these proteins
are regulated to the same extent by either T3 or T2, highlighting
a common effect of the two iodothyronines.
T2 specifically decreased proteins such as fatty acid-binding
protein (spot 31), succinyl-CoA ligase (spot 38), and glycerol
kinase (spot 42), which are involved in lipid, oxidative, and
carbohydrate metabolism, respectively (Figure 5A). In contrast,
glycerol-3-phosphate dehydrogenase (spot 68) and isocitrate
dehydrogenase [NAD] (spot 58), involved in oxidative and
substrate metabolism, were significantly increased only by T3
(Figure 5B). As a whole, these results suggest that, at the
doses used, T2 and T3, although modulating overlapping
metabolic events (e.g., amino acid and intra-mitochondrial
energy metabolism), also have their own specific molecular
targets.
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FIGURE 1 | Effects of T3 and T2 on the hepatic proteome in Ldlr−/− mice. (A) Representative 2D-E Coomassie Blue stained maps of total liver soluble proteins
extracted from Ldlr−/−, Ldlr−/−+T2, and Ldlr−/−+T3 mice and separated on 17 cm/pH 4–7 IPG strips in the first dimension and on 12% SDS-PAGE in the second.
Spotted and identified proteins among those with a density that differed significantly (by at least 0.5- or 2-fold; p < 0.05) between Ldlr−/− and either Ldlr−/−+T2 or
Ldlr−/−+T3 (blue spots) (B), Ldlr−/− and Ldlr−/−+T2 only (red spots) (C), and Ldlr−/− and Ldlr−/−+T3 only (green spots) (D). Overlapped circles represent the
total amount of differentially expressed proteins between the experimental groups. The blue area represents the percentage of proteins affected by both T2 and T3
(iodothyronines’ common proteomic effect in liver of Ldlr−/− mice) (E); the red area represents the percentage of proteins affected only by T2 treatment (F); the green
area represents the percentage of proteins affected only by T3 treatment (G).
IPA Analysis of Potential Target Proteins
Involved in T2 and T3 Effects
To further characterize the effects elicited by either T2-
or T3-treatment in liver of Ldlr−/− mice, proteomic data
were analyzed by using the IPA platform that, based on
known interactions between affected proteins, defines common
functional and canonical pathways as well as protein networks,
thereby offering additional information about the complex
interactive links between modulated proteins following the
treatments under study. The in silico analysis confirmed
that the most significant T2/T3- dependent changes altered
lipid-, amino acid-, carbohydrate-, and energy- metabolism
(Supplementary Material 2). These changes are mediated
by effects on pathways such as glycolysis/gluconeogenesis,
citrate cycle, pentose phosphate, glutathione, and amino acid
metabolism (Figures 6A,B). Overall, in terms of modulated
functions and pathways, T2 and T3 exerted a similar effect with a
few exceptions. Of particular metabolic relevance the peroxisome
proliferator-activated receptor α (PPARα)/retinoid X receptor α
(RXRα) pathway was affected only by T3 (Figure 6B).
The protein network analysis for T2 produced the highest
scored node (the value being 28) corresponding to the hepatocyte
nuclear factor 4α (HNF4α), a nuclear receptor well known
to act as a master regulator of liver-specific gene expression
orchestrating lipid and cholesterol metabolism (Figure 7A).
HNF4α is directly interconnected with some focus proteins
acquired in 2D-E analysis such as aldehyde dehydrogenase
(ALDH2, ALDH1), malate dehydrogenase (MDH1), and fatty
acid-binding protein (FABP), which are involved in substrate
and lipid metabolism (Figure 7A). Strictly in line with the
pathways analysis, as far as T3 effects are concerned, network
tool revealed PPARα as the main hub of the highest scored
network (IPA score 30), a nuclear receptor that regulates diverse
aspects of lipid metabolism, including fatty acid oxidation,
Frontiers in Physiology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 545
Moreno et al. Iodothyronines and LDL-R-Independent Hepatic Pathways
FIGURE 2 | Effects of T3 and T2 on the intrahepatic content of ApoE
and ApoA1 in Ldlr−/− mice. Representative subsections of 2D-E images of
livers of Ldlr−/−, Ldlr−/−+T2, and Ldlr−/−+T3 mice are reported. Results
are expressed as arbitrary units (means ± SD; n = 4).
FIGURE 3 | T3- and T2-dependent differential expression in liver of
Ldlr−/− mice: increased proteins. Representative subsections of 2D-E
images of livers of Ldlr−/−, Ldlr−/−+T2, and Ldlr−/−+T3 mice. Results are
expressed as arbitrary units (means ± SD; n = 4) (p < 0.05).
and lipoprotein metabolism (Figure 7B). Within the network,
PPARα directly interacts with some focus proteins acquired
in 2D-E analysis such as aldehyde dehydrogenase (ALDH2),
mitochondrial glycerol-3-phosphate dehydrogenase (GPD2),
maleylacetoacetate isomerase (GSTZ1), major urinary protein
1 (MUP1), and peroxiredoxin-6 (PRDX6), all of which are
involved in substrate and energymetabolism and in cellular stress
(Figure 7B).
Nuclear Factors Affected By T2 and T3 in
Liver of Ldlr−/− Mice
Considering that IPA network analysis highlighted HNF4α and
PPARα as the highest scored nodes grouping the major number
of interactions with differentially regulated proteins by T2 and
T3, respectively, Western blot analysis was performed to further
investigate the putative involvement of such nuclear factors into
the hypocholesterolemic effects of both iodothyronines. Both T2
and T3 administration to Ldlr−/− mice produced a significant
reduction of the nuclear content of HNF4α, with the effect
being slightly stronger in Ldlr−/−+T2 than in Ldlr−/−+T3 mice
(Figures 8A,B). By contrast, only T3 administration produced a
pronounced and significant decrease of nuclear PPARα levels vs.
those in control Ldlr−/− mice. According to what is suggested by
the in silico analysis, this result is consistent with the hypothesis
that PPARα has a specific role in the metabolic effects exerted by
T3 in Ldlr−/− mice.
In view of the fact that a partnership of HNF4α with
its coactivator, peroxisome proliferator-activated receptor γ
FIGURE 4 | T3- and T2-dependent differential expression in liver of
Ldlr−/− mice: decreased proteins. Representative subsections of 2D-E
images of livers of Ldlr−/−, Ldlr−/−+T2, and Ldlr−/−+T3 mice. (A) Enzymes
involved in amino acid metabolism. (B) Enzymes involved in substrate
metabolism. (C) Proteins involved in cellular stress. Results are expressed as
arbitrary units (means ± SD; n = 4) (p < 0.05).
coactivator-1α (PGC-1α) in the regulation of lipoprotein
metabolism has been characterized (Rhee et al., 2006), the
effect of T2 and T3 on the hepatic nuclear content of PGC-1α
was analyzed. As shown in Figures 8A,B, only T2 significantly
reduced expression levels of PGC-1α, hence suggesting an
impaired PGC-1α/HNF4α-dependent signaling in the plasma
cholesterol-lowering effects of T2.
Nuclear receptors other than HNF4α and PPARα also
participate in the transcriptional regulation of key factors
involved in the intrahepatic cholesterol metabolism. Specifically,
it has been reported that T3 exerts its hypocholesterolemic
effect mainly by binding to liver TRβ but, in the absence
of this, also acting through the liver X receptor α (LXRα)
(Gullberg et al., 2000). Nuclear receptor expression levels may
be predictive for the activity of their ligands. In view of this
and considering that LXRα is a central hepatic cholesterol
sensor, Western blot analysis was performed to verify whether
the hypocholesterolemic effect of T2 and T3 in Ldlr−/− mice
correlates with LXRα and TRβ hepatic expression levels. In
parallel with the lower plasma cholesterol levels detected
in Ldlr−/−+T2 and Ldlr−/−+T3 mice (vs. Ldlr−/−), both
iodothyronines reduced LXRα nuclear content (Figures 8A,B).
Of note, LXRα nuclear content tended to increase when Ldlr−/−
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FIGURE 5 | Iodothyronine specific effects on differential expression in
liver of Ldlr−/− mice. (A) Representative T2 specific affected proteins. (B)
Representative T3 specific affected proteins. Results are expressed as
arbitrary units (means ± SD; n = 4) (p < 0.05).
mice were consuming the WTD (Figures 8C,D). A significant
reduction of TRβ levels (about −60% vs. Ldlr−/− control mice)
was observed only in Ldlr−/−+T3 mice (Figures 8C,D).
Nuclear Factors Affected by T2 and T3 in
Livers of WT Mice
In order to evaluate whether the absence/presence of LDLr
might be a major determinant of the effects of T2 and T3 on
the expression level of the aforementioned transcription factors,
Western blot analyses were performed on liver tissue from WT
mice fed either chow diet or WTD. The effects elicited by T2
on HNF4α, PGC-1α, and LXRα levels in livers from Ldlr−/−
mice were not observed in WT mice fed chow or WTD while T3
treatment, without significantly altering PPARα nuclear content,
increased both HFN4α and PGC-1α hepatic levels, in WTD WT
mice (Supplementary Material 3).
Finally, due to the large dose of T2 used, we sought to exclude
displacement of T3 from thyroid binding globulin as a reason for
the efficacy of the T2-treatment. To do this, we assessed serum
FT3 and FT4 levels in T2 treated mice; neither was increased
[the actual values being for FT3 (pg/ml): 8.55 ± 1.8; 3.2 ± 1.9∗;
for FT4 (ng/dl): 1.24 ± 0.8; 0.15 ± 0.06∗, in WTD WT and
WTD-WT+T2 animals, respectively; ∗P < 0.05 vs. WTD WT].
Therefore, T2 did not displace T3 from the thyroid binding
globulin. Thus, increased endogenous T3 does not account for
the effects of T2.
DISCUSSION
Although it has been hypothesized on the basis of in vitro studies
that THs mediate lowering of LDL-C primarily by increased
hepatic expression of LDLr (Lopez et al., 2007) and that they
up regulate scavenger SR-B1 in mice (Johansson et al., 2005),
very recently, we (Goldberg et al., 2012) and others (Lin et al.,
2012) reported that THs can reduce serum cholesterol via a LDLr-
independent mechanism. Ldlr−/− mice have modestly elevated
levels of plasma cholesterol but when fed a WTD they develop
much higher levels of cholesterol and atherosclerosis. When
treated with high doses of T3 or T2, WTD-fed Ldlr−/− mice
showed a dramatic decrease in LDL-C with these reductions
being linked to reductions in ApoB48 and ApoB100 secretion
(Goldberg et al., 2012).
Utilizing 2D-E and MS, we studied a total proteome of 450
liver proteins and identified 25 proteins affected by both T2 and
T3, 18 only by T3 and 9 only by T2. At the used doses, both T2
and T3 impact liver proteome producing a general decrease of
modulated proteins.
When the differentially expressed proteins were mapped for
the identification of canonical pathways and biological functions
(among which lipid, carbohydrate and amino acid metabolism),
14 pathways/lists with the highest statistical significance were
identified for both iodothyronines. By comparing these lists,
3 non-overlapping pathways were identified for one of the
two iodothyronines (e.g., of particular metabolic relevance,
PPARα/RXRα activation for T3). This indicates the existence of
common proteomic targets for T2 and T3 as well as of specific
ones.
Of note, among the individual common proteins increased
by both iodothyronines, we identified MUP1. Although the
physiological functions of this low molecular weight secreted
protein belonging to the lipocalin family remain poorly
understood, recent evidence demonstrated that MUP1 could be
positively correlated with energy expenditure, metabolism, and
insulin sensitivity in mice (Hui et al., 2009). This might open new
perspectives in understanding themechanisms through which T3
and T2 determine the whole animal metabolic state (for recent
review see, Mullur et al., 2014; Goglia, 2015; Davis et al., 2016).
Key enzymes involved in amino acid- and substrate-
metabolism and cellular stress were all individual common
proteins decreased by both iodothyronines. Specifically,
the reduction of catechol O-methyltransferase, ornithine
aminotransferase, and histidine ammonia-lyase indicates a
suppressive effect elicited by both T2 and T3 on enzymes
involved in amino acid degradation and ureagenesis, which is
in line with the known effects of thyroid hormone on ammonia
metabolism (Sochor et al., 1981; Marti et al., 1988). The reduction
in the expression levels of lactoylglutathione lyase and aldehyde
dehydrogenase, on the other hand, indicates a lower content of
detoxifying enzymes in the liver of Ldlr−/− mice treated with
either T2 or T3. Of note, consistent with what was previously
reported (Silvestri et al., 2006), we observed an iodothyronine-
induced decrease of the hepatic level of regucalcin, suggesting
a role of calcium availability in the cellular effects of T2 and T3
(Del Viscovo et al., 2012).
Only T3 increased the mitochondrial enzymes glycerol-
3-phosphate dehydrogenase and isocitrate dehydrogenase.
This suggests that T3, in Ldlr−/− mice, might stimulate
mitochondrial respiration and substrate oxidation. In
particular, glycerol-3-phosphate dehydrogenase is a
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FIGURE 6 | T3 and T2 affected canonical pathways in liver of Ldlr−/− mice: in silico analysis. The lists of differentially expressed proteins were input into the
IPA platform (Ingenuity® Systems, http://www.ingenuity.com) for functional enrichment analysis. Over-represented canonical pathways for Ldlr−/−+T2 (A) and
Ldlr−/−+T3 (B) vs. Ldlr−/− deregulated proteins are represented in barplots by their statistical score (negative logarithm to the base 10 of B-H corrected p-value)
with a threshold of 1.3 (yellow straight line). The ratio between deregulated and all proteins of a pathway is also reported (yellow not straight line).
well-established marker of liver thyroid status (Rauchová
et al., 2011).
Analyzing the functional interaction between the identified
differentially expressed target proteins, the network tool revealed
sub networks centered around HNF4α for T2 and around PPARα
for T3.
HFN4α, an orphan member of the nuclear receptor
superfamily, is crucial for the maintenance and regulation of
hepatic lipid metabolism and it is a major in vivo regulator of the
expression of liver-specific genes involved in the production and
clearance of apolipoproteins (Yin et al., 2011). Odom et al. (2004)
reported that HFN4α directly binds to almost 50% of the actively
transcribed hepatic genes whereas no other transcription factor
binds to more than 1/5 of that number. In humans, Medica 16,
an HFN4α antagonist, acts as a hypolipidemic agent likely due to
reduced activation of HFN4α target gene expression (Hertz et al.,
2001; Sheena et al., 2005; Rufibach et al., 2006). The identification
ofHFN4α as a central node in the proteomic effects of T2 suggests
that this receptor could be involved in the hypocholesterolemic
effect elicited by T2 in Ldlr−/−mice. Indeed, accordingly with the
dramatic reduction in circulating apoB-containing lipoproteins,
nuclear HFN4α protein content was strongly decreased in liver
fromWTD-Ldlr−/− mice following T2 treatment.
Interacting proteins are crucial in determining the
transcriptional activity of nuclear receptors. The PGC-
1α/HFN4α partnership plays a crucial role in hepatic lipoprotein
metabolism (lipoprotein synthesis and export) (Rhee et al.,
2006), and modulation of PGC-1α coactivation of HFN4α may
provide a novel mechanism to manage dyslipidemia (Rhee et al.,
2006). Nuclear hepatic PGC-1α content was reduced by T2,
thus suggesting affected PGC-1α- HFN4α-dependent signaling
in the plasma cholesterol-lowering effects of T2. This might
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FIGURE 7 | T3 and T2 affected protein networks in liver of Ldlr−/− mice. Network representation of the molecular relationships between identified, differentially
expressed proteins (Ingenuity Systems Ltd.) in liver of Ldlr−/−+T2 (A) and Ldlr−/−+T3 (B) vs. Ldlr−/− mice. Gene products are represented as nodes, and the
biological relationship between two nodes is represented as an edge (line). Indirect interactions appear as broken lines, whereas direct interactions appear as solid
lines. All edges shown are supported by at least 1 reference from the literature, from a textbook, or from canonical information stored in the Ingenuity Pathways
Knowledge Base. Human, mouse, and rat orthologues of a gene are stored as separate objects in IPKB, but are represented as a single node in the network. For
clarity, network shapes are shown.
be correlated with the decreased hepatic level of ApoE as well
as the decreased plasma levels of ApoB48 and ApoB100 and
decreased Srb1 mRNA levels (Goldberg et al., 2012). When
compared with T2, T3 decreased HFN4α nuclear content while
not affecting that of PGC-1α, likely indicating that the observed
T2/T3-hypocholesterolemic effect depend on different molecular
events. Besides PGC-1α, another coactivator of HFN4α is
FABP, which has been shown to structurally and functionally
bind HNF4α to stimulate its transcriptional activity (McIntosh
et al., 2013). The significantly lower level of FABP in liver from
WTD-Ldlr−/− mice only following T2 treatment is in line with
the decreased expression of HNF4α and its protein targets.
Among these, of a particular interest could be the glycerol kinase
(GK), an enzyme involved in supplying glucogenic precursors
for hepatic glucose production. The GK promoter contains a
functional HNF4α binding site (Stepanian et al., 2003) and the
hepatic content of this enzyme was significantly decreased only
in T2-treated mice. By contrast, T3 treatment, while decreasing
liver HNF4α levels, did not decrease those of FABP. Moreover,
the lack of a significant effect of T3 on GK liver content might
suggest a differential impact of the two iodothyronines on hepatic
glucose production and thus on the whole animal glycaemia.
This would require further analyses above all considering the
well-known insulin antagonizing effect of T3 and the recently
described insulin sensitizing action of T2 (de Lange et al., 2011;
Moreno et al., 2011; Padron et al., 2014).
Reduction of PPARα levels was found only following T3
treatment and it is in accordance with the lower levels of HDL
and Srb1 mRNA as well as the increased hepatic triglyceride
secretion (Goldberg et al., 2012). Although PPARα activation
by fibrates decreases ApoB-containing lipoproteins as well as
total serum ApoB levels in rodents and human (Peters et al.,
1997; Milosavljevic et al., 2001), treatment of Ldlr−/− mice with
ciprofibrate markedly decreased plasma ApoB-48-carrying IDL
and LDL but at the same time caused a marked accumulation of
ApoB-100 carrying IDL/LDL, increased plasma cholesterol levels
and promoted aortic atherosclerosis (Fu et al., 2004). Our finding
of a T3-induced decrease in PPARα levels associated with a
significant reduction in plasma cholesterol and ApoB-containing
lipoproteins levels as well decreased hepatic production of
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FIGURE 8 | Effects of T3 and T2 on nuclear factors in liver of Ldlr −/− mice. (A) Representative Western blot analyses of HNF4α, PGC-1α, PPARα, and LXRα
protein levels in Ldlr−/−, Ldlr−/−+T2, and Ldlr−/−+T3 mice. Liver nuclear protein contents were normalized on α-tubulin. Protein load was 30 µg/lane. (B)
Quantitative analysis of protein expression levels. Results are expressed as arbitrary units (means ± SD; n = 3). Bars labeled with dissimilar letters are significantly
different (p < 0.05). (C) Representative Western blot analyses of LXRα and TRβ protein levels in Ldlr−/− mice fed with either a chow (Ldlr−/− C) or a western type diet
(Ldlr−/− WTD) and treated with T3 (Ldlr−/− WTD+T3). Liver nuclear protein contents were normalized on α-tubulin. Protein load was 30 µg/lane. The vertical lines
indicate cuts in the membranes to avoid to display samples not related to the used model. (D) Quantitative analysis of nuclear protein content of LXRα and TRβ in
Ldlr−/− C, Ldlr−/− WTD and Ldlr−/− WTD+T3 mice. Results are expressed as arbitrary units (means ± SD; n = 4). Bars labeled with dissimilar letters are
significantly different (p < 0.05).
ApoB-100, is in line with the above study and supports the
cholesterol-lowering effect of T3 in a situation in which the
IDL/LDL lipoprotein remnants cannot be efficiently cleared from
the plasma via the LDLr pathway. In the context of our results,
it is interesting to note that PPARα is a target of HNF4α
(Pineda Torra et al., 2002; Martinez-Jimenez et al., 2010) and
that T3 by reducing HNF4α levels likely produces a downstream
negative effect on PPARα which, indeed, could not be the case
with T2, that did not significantly reduce PPARα levels vs.
controls. So although both T2 and T3 reduce HNF4α levels,
likely they target different intrahepatic pathways all leading to the
hypocholesterolemic effect in Ldlr−/− mice.
Whether specifically targeting HNF4α- and PPARα-
downstream proteins will reproduce the LDL reduction
found with thyroid hormones is an area for future studies also
based on in vitro approaches. Moreover, we should note that
2D-E based proteomic analyses are intrinsically limited as they
resolve only soluble and highly expressed components of protein
mixtures, and as the detection of low and high molecular mass
or of basic and hydrophobic proteins is inefficient. Thus, other
factors missing in our analysis could also be critical for the
hypocholesterolemic effects of iodothyronines.
Besides the above mentioned nuclear receptors, LXRα, by
regulating expression of several genes (Calkin and Tontonoz,
2010), controls cholesterol clearance via regulation of intestinal
cholesterol absorption, biliary cholesterol secretion and
cholesterol conversion into bile acids. Both T3 and T2 lowered
nuclear LXRα protein content. One competitor receptor of
LXRα in mediating the hypocholesterolemic effect of T3, is
TRβ (Gullberg et al., 2000). According to the hyperthyroid
state of the animals, hepatic nuclear content of TRβ was
significantly decreased only in T3-treated mice. The lack of T2
effects on TRβ levels, at the high dose of T2 used, considering
the low, but not ignorable, affinity of T2 for TRβ, might
stimulate to further investigate how T2 might exert some
of its transcriptomic/proteomic effects in a TR-dependent
manner (Mendoza et al., 2013; Navarrete-Ramírez et al., 2014;
Orozco et al., 2014; Jonas et al., 2015), above all in view of
the fact that, as already shown by Goldberg et al. (2012) in
Ldlr−/− mice, also in WT mice, the high used dose of T2
significantly suppressed FT3 and FT4 levels. Moreover, as far
as it concerns the differences between the actions exerted by
T3 and T2, it has to be considered that only one dose of each
iodothyronine was used and T2 was administered at a much
higher concentration than T3, so that it would be expected
that differences in response, apart from involving different
mechanisms, might also reflect differences in the dose/response
curve.
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T2-mediated effects on HNF4α, PGC-1α, and LXRα levels
were not observed in WT mice either when fed with Chow or
WTD. On the other hand, T3 lead to increased HFN4α and
PGC-1α levels inWTWTD fedmice. Thus, the absence/presence
of LDLr may be a major determinant of the effects that T2 and T3
exert on the above nuclear factors.
In conclusion, although there are differences among mice,
humans and rats regarding cholesterol hepatic metabolism, this
study, independently of the specific effects elicited by the high
used doses of T2 and T3, furnishes novel information on LDLr-
independent pathways and mediators that could be important
targets for cholesterol lowering therapies.
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